Back to results
US 2006/0233804 A1Published application
IGF antagonist peptides
AssigneeGenentech, Inc.
InventorsKurt Deshayes, Henry Lowman, Michelle Schaffer, Sachdev Sidhu
Life of this patent
Estimating the term…
Abstract
Peptides are provided that antagonize the interaction of IGF-1 with its binding proteins, insulin receptor, and IGF receptor. These IGF antagonist peptides are useful in treating disorders involving IGF-1 as a causative agent, such as, for example, various cancers.
Claims16
A method for treating a mammal having a disorder involving an insulin-like growth factor-1 (IGF-1)-mediated event comprising administering to the mammal an effective amount of the peptide comprising the sequence:
- (Xaa)1(Xaa)2Cys(Xaa)3(Xaa)4SerVal(Xaa)5AlaLeu(Xaa)6(Xaa)7CysMet(Xaa)8 (SEQ ID NO:1), where (Xaa)1, (Xaa)2, and (Xaa)7 are an amino acid, (Xaa)3 is Phe, Leu or Tyr, (Xaa)4 is Glu, Asp, Ala, Gly, Thr, or Ser, (Xaa)5 is Glu, Asp, Ala, or Gly, (Xaa)6 is Arg or Lys, and (Xaa)8 is Tyr or Arg.
Dependencies are inferred from the claim text.